Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin (Q36773485)

16 August 2017

1 reference

title

Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin (English)

1 reference

16 August 2017

1 reference

Herman GA

1

1 reference

16 August 2017

Stein PP

series ordinal

2

1 reference

16 August 2017

Thornberry NA

series ordinal

3

1 reference

16 August 2017

Wagner JA

series ordinal

4

1 reference

16 August 2017

language of work or name

English

0 references

publication date

28 March 2007

1 reference

Clinical Pharmacology & Therapeutics

16 August 2017

published in

1 reference

16 August 2017

volume

81

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

761-767

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Biological actions and therapeutic potential of the glucagon-like peptides

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Multiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100167

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100167

1 reference

16 August 2017

1 reference